No better than less expensive drugs

The meta-analysis of short term studies using dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes indicates that they lower glycated haemoglobin (HbA1C) without causing weight gain or increasing mortality or serious adverse events. 1 In return, they increase drug costs. Some treatment stra...

Full description

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2012-04, Vol.344 (apr24 1), p.e2914-e2914
Main Authors: Perry, Thomas L, Lippman, Stephen S, McConnell, Mark, Tejani, Aaron M
Format: Article
Language:English
Subjects:
Cost-Benefit Analysis
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-peptidase IV
Dipeptidyl-Peptidase IV Inhibitors - economics
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Drugs
Glucose
Hemoglobin
Humans
Hypoglycemic Agents - economics
Hypoglycemic Agents - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The meta-analysis of short term studies using dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes indicates that they lower glycated haemoglobin (HbA1C) without causing weight gain or increasing mortality or serious adverse events. 1 In return, they increase drug costs. Some treatment strategies, including guideline emphasis on lower capillary blood glucose and HbA1C targets, increase harms, including death. 3 Pioglitazone and rosiglitazone significantly reduce HbA1C but do not improve cardiovascular outcomes, while increasing heart failure. 4 Rosiglitazone also increases myocardial infarctions. 5 Cost effectiveness cannot be assessed until we know whether DPP-4 inhibitors are effective for the real goals of treatment.
ISSN:0959-8138
1756-1833
1756-1833
DOI:10.1136/bmj.e2914